These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28977823)

  • 21. Breast cancer following ovarian cancer in BRCA mutation carriers.
    Gangi A; Cass I; Paik D; Barmparas G; Karlan B; Dang C; Li A; Walsh C; Rimel BJ; Amersi FF
    JAMA Surg; 2014 Dec; 149(12):1306-13. PubMed ID: 25372568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
    Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic approaches for women predisposed to breast cancer.
    Nathanson KL; Domchek SM
    Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
    Long KC; Kauff ND
    Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F
    Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer after bilateral risk-reducing mastectomy.
    Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
    Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
    Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
    J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.